Drug Testing Market Size

Global Drug Testing Market size was valued at USD 5.9 billion in 2023 and is poised to grow from USD 6.21 billion in 2024 to USD 9.31 billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies in order to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. The key market players are also constantly focused on R&D in order to supply industries with the most efficient and cost-effective solutions. 'Laboratory Corporation of America Holdings (LabCorp) (USA) ', 'Abbott Laboratories (USA) ', 'Thermo Fisher Scientific Inc. (USA) ', 'Siemens Healthineers AG (Germany) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'OraSure Technologies, Inc. (USA) ', 'Alfa Scientific Designs, Inc. (USA) ', 'Drägerwerk AG & Co. KGaA (Germany) ', 'Randox Testing Services (UK) ', 'United States Drug Testing Laboratories, Inc. (USDTL) (USA) ', 'Psychemedics Corporation (USA) ', 'Cordant Health Solutions (USA) ', 'Omega Laboratories, Inc. (USA) ', 'Clinical Reference Laboratory, Inc. (USA) ', 'Premier Biotech, Inc. (USA) ', 'Danaher Corporation (USA) ', 'Bio-Rad Laboratories, Inc. (USA) ', 'Shimadzu Corporation (Japan) ', 'Lifeloc Technologies, Inc. (USA)'

The key factor that drives the growth of the market is growing drugs and alcohol consumption. Drug and alcohol abuse are on the rise all around the world. According to the World Drug Report 2021, an estimated 275 million persons worldwide aged 15-64, or one in every 18 in that age group, used drugs at least once in the preceding year in 2019 (range: 175 million to 374 million). Drug use problems were expected to affect 36.3 million people, or over 13% of the global population, in 2019. In the same year, drug use killed about 500,000 people, while drug use disorders resulted in the loss of 18 million years of healthy life, primarily owing to opioids. Similar increases in alcohol intake have been observed, with the result being an increase in the prevalence of impaired driving. The increased consumption of illicit substances and alcohol will drive the development of drug screening goods and services on the road, consequently boosting market growth overall.

Fingerprint-based drug testing is a new concept that has gained traction as a result of the COVID-19 pandemic. The coronavirus has made drug testing in hospitals, labs, and other facilities problematic due to the danger of viral transmission. Although fingerprint-based drug screening can help prevent the spread of COVID, it is noninvasive, portable, less time-consuming, hygienic, allows for social distancing, is user-friendly, and does not necessitate any special preparation for sample collection and processing. This test is simple to administer whenever and wherever it is needed, providing flexible and effective workplace drug testing. To detect drugs and drug metabolites, the test analyses microscopic traces of sweat in the fingerprint. This test is utilized in the workplace, criminal justice, law enforcement, and drug treatment program. To detect drugs and drug metabolites, the test analyses microscopic traces of sweat in the fingerprint. If extensively used, this test is projected to replace urine, hair, and blood-based drug tests. This is a big opportunity for market participants in the drug screening sector to capitalize on.

In 2021, North America is expected to have the biggest market share. The North American market's dominance is attributed to factors such as rising illicit drug consumption, the availability of government funding to combat drug abuse, laws supporting drug screening, the rising burden of accidents caused by alcohol impairment, and the presence of key players in the region, all of which are driving the growth of the drug testing market in this region. Certain factors, such as an increase in the number of drug and alcohol misuse cases and the strict enforcement of regulations. New organ-on-a-chip technologies provide more precise and accurate perception of pharmacological effects on the human body. Organ-on-a-chip advancements are also contributing to the expansion of the North American drug testing market.